Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load
Few data are available regarding the use of tenofovir disoproxil fumarate (TDF) during pregnancy for the prevention of mother-to-child transmission of hepatitis B virus (HBV). In this trial, we included 200 mothers who were positive for hepatitis B e antigen (HBeAg) and who had an HBV DNA level higher than 200,000 IU per milliliter. Participants were randomly assigned, in a 1:1 ratio, to receive usual care without antiviral therapy or to receive TDF (at an oral dose of 300 mg per day) from 30 to 32 weeks of gestation until postpartum week 4; the participants were followed until postpartum week 28. All the infants received immunoprophylaxis. The primary outcomes were the rates of mother-to-child transmission and birth defects. The secondary outcomes were the safety of TDF, the percentage of mothers with an HBV DNA level of less than 200,000 IU per milliliter at delivery, and loss or seroconversion of HBeAg or hepatitis B surface antigen at postpartum week 28. At delivery, 68% of the mothers in the TDF group (66 of 97 women), as compared with 2% in the control group (2 of 100), had an HBV DNA level of less than 200,000 IU per milliliter (P<0.001). At postpartum week 28, the rate of mother-to-child transmission was significantly lower in the TDF group than in the control group, both in the intention-to-treat analysis (with transmission of virus to 5% of the infants [5 of 97] vs. 18% [18 of 100], P=0.007) and the per-protocol analysis (with transmission of virus to 0 vs. 7% [6 of 88], P=0.01). The maternal and infant safety profiles were similar in the TDF group and the control group, including birth-defect rates (2% [2 of 95 infants] and 1% [1 of 88], respectively; P=1.00), although more mothers in the TDF group had an increase in the creatine kinase level. After the discontinuation of TDF, alanine aminotransferase elevations above the normal range occurred more frequently in mothers in the TDF group than in those in the control group (45% [44 of 97 women] vs. 30% [30 of 100], P=0.03). The maternal HBV serologic outcomes did not differ significantly between the groups. In a cohort of HBeAg-positive mothers with an HBV DNA level of more than 200,000 IU per milliliter during the third trimester, the rate of mother-to-child transmission was lower among those who received TDF therapy than among those who received usual care without antiviral therapy. (Funded by Gilead Sciences; ClinicalTrials.gov number, NCT01488526.)..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:374 |
|---|---|
| Enthalten in: |
The New England journal of medicine - 374(2016), 24, Seite 2324-2334 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pan, Calvin Q [VerfasserIn] |
|---|
| Links: |
|---|
| RVK: |
|---|
| doi: |
10.1056/NEJMoa1508660 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1978162200 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1978162200 | ||
| 003 | DE-627 | ||
| 005 | 20230517093249.0 | ||
| 007 | tu | ||
| 008 | 160719s2016 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1056/NEJMoa1508660 |2 doi | |
| 028 | 5 | 2 | |a PQ20160719 |
| 035 | |a (DE-627)OLC1978162200 | ||
| 035 | |a (DE-599)GBVOLC1978162200 | ||
| 035 | |a (PRQ)c1496-7edab70a8528f8091ad0dce04152780e936fecb2d637bdc45bdf4719324b56670 | ||
| 035 | |a (KEY)0171808820160000374002402324tenofovirtopreventhepatitisbtransmissioninmothersw | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 084 | |a XA 10000 |q AVZ |2 rvk | ||
| 084 | |a 44.60 |2 bkl | ||
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a Pan, Calvin Q |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Few data are available regarding the use of tenofovir disoproxil fumarate (TDF) during pregnancy for the prevention of mother-to-child transmission of hepatitis B virus (HBV). In this trial, we included 200 mothers who were positive for hepatitis B e antigen (HBeAg) and who had an HBV DNA level higher than 200,000 IU per milliliter. Participants were randomly assigned, in a 1:1 ratio, to receive usual care without antiviral therapy or to receive TDF (at an oral dose of 300 mg per day) from 30 to 32 weeks of gestation until postpartum week 4; the participants were followed until postpartum week 28. All the infants received immunoprophylaxis. The primary outcomes were the rates of mother-to-child transmission and birth defects. The secondary outcomes were the safety of TDF, the percentage of mothers with an HBV DNA level of less than 200,000 IU per milliliter at delivery, and loss or seroconversion of HBeAg or hepatitis B surface antigen at postpartum week 28. At delivery, 68% of the mothers in the TDF group (66 of 97 women), as compared with 2% in the control group (2 of 100), had an HBV DNA level of less than 200,000 IU per milliliter (P<0.001). At postpartum week 28, the rate of mother-to-child transmission was significantly lower in the TDF group than in the control group, both in the intention-to-treat analysis (with transmission of virus to 5% of the infants [5 of 97] vs. 18% [18 of 100], P=0.007) and the per-protocol analysis (with transmission of virus to 0 vs. 7% [6 of 88], P=0.01). The maternal and infant safety profiles were similar in the TDF group and the control group, including birth-defect rates (2% [2 of 95 infants] and 1% [1 of 88], respectively; P=1.00), although more mothers in the TDF group had an increase in the creatine kinase level. After the discontinuation of TDF, alanine aminotransferase elevations above the normal range occurred more frequently in mothers in the TDF group than in those in the control group (45% [44 of 97 women] vs. 30% [30 of 100], P=0.03). The maternal HBV serologic outcomes did not differ significantly between the groups. In a cohort of HBeAg-positive mothers with an HBV DNA level of more than 200,000 IU per milliliter during the third trimester, the rate of mother-to-child transmission was lower among those who received TDF therapy than among those who received usual care without antiviral therapy. (Funded by Gilead Sciences; ClinicalTrials.gov number, NCT01488526.). | ||
| 650 | 4 | |a Tenofovir - adverse effects | |
| 650 | 4 | |a Antiviral Agents - therapeutic use | |
| 650 | 4 | |a Hepatitis B, Chronic - virology | |
| 650 | 4 | |a Alanine Transaminase - blood | |
| 650 | 4 | |a Hepatitis B e Antigens - blood | |
| 650 | 4 | |a Hepatitis B, Chronic - drug therapy | |
| 650 | 4 | |a DNA, Viral - blood | |
| 650 | 4 | |a Tenofovir - therapeutic use | |
| 650 | 4 | |a Pregnancy Complications, Infectious - drug therapy | |
| 650 | 4 | |a Creatine Kinase - blood | |
| 650 | 4 | |a Antiviral Agents - adverse effects | |
| 650 | 4 | |a Hepatitis B virus - genetics | |
| 650 | 4 | |a Infectious Disease Transmission, Vertical - prevention & control | |
| 650 | 4 | |a Hepatitis | |
| 650 | 4 | |a Drug therapy | |
| 650 | 4 | |a Mothers | |
| 650 | 4 | |a Viral infections | |
| 650 | 4 | |a Maternal & child health | |
| 650 | 4 | |a Disease transmission | |
| 650 | 4 | |a Pregnancy | |
| 650 | 4 | |a Preventive medicine | |
| 700 | 1 | |a Duan, Zhongping |4 oth | |
| 700 | 1 | |a Dai, Erhei |4 oth | |
| 700 | 1 | |a Zhang, Shuqin |4 oth | |
| 700 | 1 | |a Han, Guorong |4 oth | |
| 700 | 1 | |a Wang, Yuming |4 oth | |
| 700 | 1 | |a Zhang, Huaihong |4 oth | |
| 700 | 1 | |a Zou, Huaibin |4 oth | |
| 700 | 1 | |a Zhu, Baoshen |4 oth | |
| 700 | 1 | |a Zhao, Wenjing |4 oth | |
| 700 | 1 | |a Jiang, Hongxiu |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d Waltham, Mass. : MMS, 1928 |g 374(2016), 24, Seite 2324-2334 |w (DE-627)129495220 |w (DE-600)207154-X |w (DE-576)014893169 |x 0028-4793 |7 nnns |
| 773 | 1 | 8 | |g volume:374 |g year:2016 |g number:24 |g pages:2324-2334 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1056/NEJMoa1508660 |3 Volltext |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/27305192 |
| 856 | 4 | 2 | |u http://search.proquest.com/docview/1797569203 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_168 | ||
| 912 | |a GBV_ILN_183 | ||
| 912 | |a GBV_ILN_290 | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2008 | ||
| 912 | |a GBV_ILN_2012 | ||
| 912 | |a GBV_ILN_2021 | ||
| 912 | |a GBV_ILN_2219 | ||
| 912 | |a GBV_ILN_2414 | ||
| 912 | |a GBV_ILN_2424 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4219 | ||
| 912 | |a GBV_ILN_4256 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4310 | ||
| 912 | |a GBV_ILN_4315 | ||
| 912 | |a GBV_ILN_4320 | ||
| 912 | |a GBV_ILN_4323 | ||
| 936 | r | v | |a XA 10000 |
| 936 | b | k | |a 44.60 |q AVZ |
| 936 | b | k | |a 44.00 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 374 |j 2016 |e 24 |h 2324-2334 | ||